Related Experiment Videos
Biomarkers in advanced heart failure: diagnostic and therapeutic insights
Vijaiganesh Nagarajan1, W H Wilson Tang
1Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, OH, USA.
Abstract:
Publications regarding the potential clinical utility of biomarker testing in the management of heart failure have been exponentially increasing over the last decade. The majority of non-cardiac biomarkers are commonly used to identify end-organ dysfunction or comorbidities. The diagnostic utility of natriuretic peptide testing has been well-established. Despite consistently demonstrating their prognostic values and some promising initial results, treatment guided by natriuretic peptide testing is still debated. Although cardiac troponins have been extensively used in diagnosis of myocardial injury, their primary use of biomarkers in advanced heart failure is prognostication and risk stratification. Congest Heart Fail. Congest Heart Fail. 2011;17:169-174. © 2011 Wiley Periodicals, Inc.
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Heart Failure II: Pathophysiology
Heart Failure VI: Adjunct Therapies
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure V: Medical Management